Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate Hypertension - PubMed
3 months ago
- #hypertension
- #combination therapy
- #clinical trial
- Single-pill low-dose triple combination therapy (LDC-ALC) compared to standard-dose monotherapy (amlodipine or losartan) in mild-to-moderate hypertension patients.
- Phase III, double-blind, active-controlled trials (HM-APOLLO-301 and HM-APOLLO-302) conducted in South Korea.
- Primary endpoint: systolic blood pressure (SBP) reduction at week 8, assessed for noninferiority and superiority.
- Results: LDC-ALC showed noninferiority to amlodipine and superiority to losartan in SBP reduction.
- LDC-ALC had similar adverse event rates compared to monotherapies, with low treatment withdrawal rates.
- Conclusion: LDC-ALC is an effective and well-tolerated initial therapy for mild-to-moderate hypertension.